Advanced Cannabinoid Medicine

Medical Necessity, Complexity Grading, Coding & Case-Based Treatment Planning

A Competency-Based Framework for the Medically Complex Cannabis Patient


PART 1 — FOUNDATIONS & PHARMACOLOGY


1 — Title, Disclosures & Course Map

Title, presenter credentials, specialty background, financial disclosures, CME accreditation, 5-part course map, 40-slide educational arc, EHR documentation gap (~33% documented), pre-test polling question, overview of evidence-based cannabinoid medicine for medically complex patients


2 — Learning Objectives & Competency Framework

Medical necessity documentation, ICD-10/DSM-5/CPT integration, ASA/complexity grading, evidence-informed treatment planning, perioperative cannabis medicine, harm reduction, multi-route cannabinoid decision-making, drug-interaction management, complex patient analysis, multidisciplinary coordination


3 — Endocannabinoid System: Clinical Pharmacology Primer

CB1 receptors = cortex/hippocampus/basal ganglia/cerebellum, CB2 receptors = immune cells/microglia/peripheral tissues, anandamide (AEA), 2-AG, THC partial CB1/CB2 agonist, CBD indirect ECS modulation, 5-HT1A agonism, GPR55 antagonism, pain signaling, mood regulation, appetite, sleep, inflammation, antiemetic pathways, CBD mitigation of THC-induced anxiety/tachycardia


4 — Cannabinoid Pharmacology & Adverse Effects

THC psychoactive effects, CBD anxiolytic/antiepileptic effects, terpenes, entourage effect, dose-response relationships, biphasic THC anxiety effects, tolerance, withdrawal, dependence, psychomotor slowing, memory impairment, dizziness, tachycardia, orthostasis, sedation, psychiatric destabilization, anti-inflammatory mechanisms


5 — Cannabinoid Formulations: FDA vs State-Regulated

Epidiolex, dronabinol, nabilone, nabiximols, oral oils, capsules, tinctures, flower, concentrates, RSO, THC:CBD ratios, FDA-approved vs dispensary products, labeling variability, contamination risk, evidence-to-product availability gap, state-specific regulation differences


6 — Routes of Administration & Pharmacokinetics

Oral, sublingual, inhaled, vaporized, topical/transdermal, onset/peak/duration, first-pass metabolism, 11-OH-THC formation, delayed edible onset, pulmonary exposure, bioavailability differences, oral overconsumption risk, topical localized therapy, route selection by age/comorbidity/psychiatric risk


7 — CYP450 Drug Interactions

CBD CYP2C19/CYP3A4 inhibition, THC CYP2C9/CYP3A4 effects, smoked cannabis CYP1A2 induction, warfarin, tacrolimus, clobazam, valproate, SSRIs, opioids, benzodiazepines, sedating antidepressants, additive CNS depression, hepatic metabolism, immunosuppressants, polypharmacy risk management, CANN-DIR interaction checker


8 — Screening Tools & DSM-5 Integration

CUDIT-R = Cannabis Use Disorders Identification Test-Revised, CAGE-AID = alcohol/drug risk screen, CAST = Cannabis Abuse Screening Test, DSM-5 Cannabis Use Disorder mild = 2–3 criteria/moderate = 4–5/severe ≥6, cannabis withdrawal syndrome, CHS screening, cyclic vomiting assessment, AGA recommendations, substance-use severity grading


9 — Functional Impairment Scales

PEG = Pain, Enjoyment, General Activity scale, Oswestry Disability Index = spinal disability grading, PCL-5 = PTSD Checklist for DSM-5, score ≥31–33 suggests PTSD, ISI = Insomnia Severity Index (0–28), PHQ-9 = depression severity questionnaire, GAD-7 = generalized anxiety severity, FIQ-R = Fibromyalgia Impact Questionnaire-Revised, ECOG/Karnofsky = oncology functional status, MoCA = Montreal Cognitive Assessment, Timed Up and Go = fall-risk assessment


10 — Harm Reduction & Evidence Hierarchy

Avoid >10% THC inhaled products, avoid >10 mg/day oral THC, oral/sublingual preferred, avoid smoking in pulmonary/CV disease, avoid cannabis + opioids/benzodiazepines/alcohol, driving precautions, age ≤25 THC caution, geriatric low-dose approach, pregnancy contraindication, FDA-approved RCTs vs observational studies, confounding bias, placebo effects, evidence-tier interpretation


PART 2 — MEDICAL NECESSITY, DOCUMENTATION & CODING


11 — 5-Pillar Medical Necessity Framework

Qualifying diagnosis, functional impairment, failed/inaccessible therapies, individualized risk-benefit analysis, monitoring/documentation, informed consent, treatment goals, multimodal care justification, symptom severity, quality-of-life impairment, cost/access barriers


12 — Informed Consent & Clinical Decision-Making

Risks/benefits/options, failed prior therapies, FDA-approved alternatives discussed, realistic treatment expectations, psychiatric/CV risks, cannabis use disorder risk, driving impairment, dependence potential, withdrawal planning, sedation counseling, route-specific risks, shared decision-making


13 — ICD-10 Coding: Qualifying Diagnoses

Chronic pain G89.29/G89.4, cancer pain G89.3, PTSD F43.10, fibromyalgia M79.7, multiple sclerosis G35, epilepsy G40.909, Crohn’s disease K50.90, Parkinson’s disease G20, insomnia G47.00, neuropathy G62.9, anxiety disorder F41.1, nausea/vomiting R11.2


14 — ICD-10 Coding: Cannabis-Related Complications

Therapeutic/uncomplicated cannabis use F12.90, cannabis abuse F12.10, dependence F12.20, withdrawal F12.23, CHS F12.188/F12.288 + R11.2, long-term therapy Z79.899, monitoring Z51.81, cannabis-induced anxiety, cannabis-induced psychosis, dehydration, AKI risk, DSM-5 linkage


15 — CPT Coding & Billing

99205 new high-complexity visit, 99214 moderate follow-up, 99215 high-complexity follow-up, 99417 prolonged services, G3002/G3003 chronic pain management, 90791/90792 psychiatric evaluation, 80305–80307 urine drug screening, SBIRT billing G0443/G2011, prolonged counseling, telehealth documentation, modifier 25


16 — Billing Optimization Pearls

Time-based billing, multimodal treatment plans, UDS justification, PDMP documentation, modifier 25, telehealth coding, cannabis counseling complexity, prolonged-service documentation, chronic pain management coding, psychiatric complexity documentation, risk stratification documentation


17 — Cannabis Patient Complexity Grading

Tier 1 low complexity, Tier 2 moderate complexity, Tier 3 high complexity, Tier 4 specialist-only complexity, ASA I healthy patient, ASA II mild systemic disease, ASA III severe systemic disease, ASA IV life-threatening disease, organ-system burden, psychiatric complexity, polypharmacy, perioperative risk


18 — Cardiovascular Risk Stratification

MI/stroke risk, CHF/CAD, tachycardia, orthostasis, exercise intolerance, angina, inhalation contraindications, AHA recommendations, young adult MI risk, arrhythmia concerns, cardiovascular mortality signal, perioperative cardiac considerations


19 — Psychiatric Risk Stratification

Psychosis risk, bipolar disorder, PTSD F43.10, anxiety F41.1, depression F32.A, suicidal ideation, THC biphasic anxiety effects, CBD anxiolytic evidence, age ≤25 THC vulnerability, dissociation, paranoia, psychiatry co-management, substance-use overlap


20 — Evidence-Informed Treatment Planning Algorithm

Indication assessment, route selection, formulation selection, CBD-dominant vs balanced THC:CBD, dosing initiation, “start low, go slow,” THC 1–2.5 mg initiation, CBD titration, harm reduction, follow-up intervals, UDS/PDMP monitoring, specialist referral criteria


PART 3 — EVIDENCE BY DIAGNOSIS & TREATMENT PLANNING


21 — Chronic Noncancer Pain

ICD-10: G89.29/G89.4/R52, prevalence: 24.3% U.S. adults chronic pain, 8.5% high-impact chronic pain, ACP guidance, BMJ meta-analysis, nabiximols, nabilone vs dronabinol, neuropathic pain evidence, opioid-sparing literature, sleep improvement, functional outcomes, CBD limitations, inhaled cannabis concerns


22 — Fibromyalgia

ICD-10: M79.7, prevalence: ~2–4% adults, widespread pain, fatigue, sleep dysfunction, anxiety/depression overlap, Mayo Clinic survey, UK Cannabis Registry, FIQ-R tracking, observational vs RCT limitations, adverse effects, quality-of-life outcomes


23 — Epilepsy Evidence: Epidiolex

ICD-10: G40.909, Dravet G40.83, Lennox-Gastaut G40.812, TSC Q85.1, prevalence: ~3.4M U.S. patients, seizure reduction, clobazam interaction, hepatotoxicity monitoring, LFT surveillance, somnolence, diarrhea, FDA-approved CBD evidence, AES/AAN guidance


24 — CINV & MS Spasticity

CINV ICD-10: R11.2 + T45.1X5A, MS ICD-10: G35, MS prevalence: ~1M U.S. patients, Grimison THC:CBD trial, ASCO guidance, refractory nausea/vomiting, appetite stimulation, palliative symptom control, breakthrough CINV, MS spasticity reduction, nabiximols evidence, NICE recommendations


25 — PTSD, Anxiety, Tourette Syndrome & Insomnia

PTSD F43.10, anxiety F41.1/F41.9, insomnia G47.00/F51.01, Tourette syndrome F95.2, anxiety prevalence ~19.1% U.S. adults annually, PTSD lifetime prevalence ~6–8%, insomnia symptoms ~30% adults, nightmare reduction, nabilone, CBD anxiety evidence, hypervigilance, psychiatric destabilization risk


26 — Cancer, Palliative Care & Survival Literature

Cancer C80.1, cancer pain G89.3, cachexia R64, palliative care Z51.5, U.S. cancer burden >2M new cases/year, appetite stimulation, nausea/vomiting, insomnia, existential distress, caregiver burden, palliative care integration, low-dose THC literature, observational survival studies, QOL improvement


27 — CHS & Cannabis-Related Complications

CHS F12.188/F12.288 + R11.2/E86.0, Rome IV criteria, concentrate exposure, cyclic vomiting, hot shower behavior, dehydration, electrolyte imbalance, AKI risk, recurrent ED visits, differential diagnosis, cessation counseling, supportive care, high-potency THC risk


28 — Neuropathy, Diabetes & Parkinson’s Disease

Neuropathy G62.9/E11.40, diabetes E11.9, Parkinson’s disease G20, diabetes prevalence >38M Americans, Parkinson’s prevalence >1.1M Americans, neuropathic pain, gait instability, insomnia overlap, fall risk, geriatric considerations, observational cannabinoid data


29 — Florida & Georgia Qualified Conditions

Florida: cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn’s disease, Parkinson’s disease, MS, terminal illness, chronic nonmalignant pain
 Georgia: cancer, ALS, epilepsy/TBI seizures, MS, Crohn’s disease, mitochondrial disease, Parkinson’s disease, sickle cell disease, Tourette syndrome, autism spectrum disorder, epidermolysis bullosa, Alzheimer’s disease, AIDS, neuropathy, hospice, intractable pain, PTSD


30 — Integrated Treatment Planning

Diagnosis + ICD-10, prevalence/context, qualifying condition status, severity grade, ASA status, failed therapies, access barriers, route selection, THC/CBD ratio, dose titration, monitoring tools, CPT/E&M level, follow-up interval, multidisciplinary referrals


PART 4 — COMPLEX PATIENT CASES & CLINICAL DECISION-MAKING


31 — Case 1: Chronic Pain & Polypharmacy

Chronic pain G89.4, lumbar pain M54.50, insomnia G47.00, anxiety F41.1, opioid therapy Z79.891, long-term medication use Z79.899, ASA III, PEG/PDI tracking, opioid reduction, temazepam taper, occupational impairment, failed PT/injections/gabapentin


32 — Case 2: Veteran With Crohn’s Disease, MS & PTSD

Crohn’s disease K50.90, MS G35, PTSD F43.10, insomnia G47.00, neuropathy G62.9, PCL-5/ISI monitoring, autoimmune overlap, bowel dysfunction, spasticity, gait instability, psychiatric risk, polypharmacy, fall-risk assessment


33 — Case 3: Cancer Surgery & Case 4: CHF/BKA

Cancer surgery: cancer C50.919/C80.1, cancer pain G89.3, nausea/vomiting R11.2, cachexia R64, anxiety F41.1, ASA III–IV, perioperative planning, appetite support, opioid minimization
 CHF/BKA: diabetic neuropathy E11.40, CHF I50.9, PVD I73.9, chronic pain G89.29, depression F32.A, phantom limb pain risk, respiratory concerns, rehabilitation planning, ASA IV


34 — Case 5: ADHD, OSA, Prior CHS & Arthroscopy

ADHD F90.9, OSA G47.33, meniscus tear S83.209A, cannabis use F12.90, CHS history Z87.898, anxiety F41.1, substance use F19.90, CUDIT-R/ISI monitoring, concentrate exposure, kratom interactions, aspiration risk, insomnia, perioperative harm reduction


35 — Ethical Challenges & Multidisciplinary Care

Autonomy vs safety, THC benefit vs psychiatric risk, cannabis vs first-line therapies, documentation/legal concerns, psychiatry, pain management, oncology, surgery/anesthesia, addiction medicine, rehabilitation, sleep medicine, pharmacy collaboration


PART 5 — TRULIEVE PRODUCTS & CLINICAL APPLICATIONS


36 — Trulieve Product Categories

Momenta THC Cream, Momenta CBD tincture, 1:1 tinctures, RSO tincture, CBD capsules, THC capsules, CBN capsules, distillate syringes, RSO syringes, Sweet Talk gels, vape carts, TruPods, whole flower, all-in-one devices


37 — Product Selection by Clinical Goal

Pain/neuropathy = ratio tincture + topical, insomnia = low-dose THC/CBN, anxiety/PTSD = CBD-dominant or balanced low-dose ratio, appetite/nausea = THC/RSO caution, breakthrough pain = rapid-onset inhalation in low-risk patients, geriatric care = low-dose oral/topical


38 — Product Selection by Risk Profile

CHF/CAD/OSA/COPD = avoid inhalation, elderly/fall risk = low-dose oral/topical, psychiatric instability = avoid high-THC concentrates, CHS history = avoid concentrates/frequent THC, polypharmacy = prefer topical/CBD-dominant options, perioperative risk modification


39 — Pharmacokinetics & CHS Prevention

Oral = delayed onset/longer acting/11-OH-THC formation, sublingual = intermediate onset, inhaled = rapid onset/higher pulmonary-CV risk, topicals = minimal systemic exposure, concentrates/high-potency THC = highest CHS risk, safer alternatives = ratio/CBD-dominant formulations


40 — Final Clinical Pearls & Future Directions

Medical necessity requires diagnosis + impairment + risk-benefit analysis + monitoring, product selection should match clinical goal and ASA risk, ratio products often better tolerated, CBD may mitigate THC adverse effects, harm reduction is essential, evidence gaps remain, multidisciplinary care improves safety, future cannabinoid research directions, Q&A


Reference List